Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer
Titel:
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer
Auteur:
Matulonis, U.A. Wulf, G.M. Barry, W.T. Birrer, M. Westin, S.N. Farooq, S. Bell-McGuinn, K.M. Obermayer, E. Whalen, C. Spagnoletti, T. Luo, W. Liu, H. Hok, R.C. Aghajanian, C. Solit, D.B. Mills, G.B. Taylor, B.S. Won, H. Berger, M.F. Palakurthi, S. Liu, J. Cantley, L.C. Winer, E.